Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
A new myositis-specific autoantibody directed against melanoma differentiation-associated gene 5 (anti-MDA5) has been described in patients with dermatomyositis (DM). We report the clinical characteristics of patients with anti-MDA5 in a large Mediterranean cohort of DM patients from a single center...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/290797 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850163950719598592 |
|---|---|
| author | Moises Labrador-Horrillo Maria Angeles Martinez Albert Selva-O'Callaghan Ernesto Trallero-Araguas Eva Balada Miquel Vilardell-Tarres Cándido Juárez |
| author_facet | Moises Labrador-Horrillo Maria Angeles Martinez Albert Selva-O'Callaghan Ernesto Trallero-Araguas Eva Balada Miquel Vilardell-Tarres Cándido Juárez |
| author_sort | Moises Labrador-Horrillo |
| collection | DOAJ |
| description | A new myositis-specific autoantibody directed against melanoma differentiation-associated gene 5 (anti-MDA5) has been described in patients with dermatomyositis (DM). We report the clinical characteristics of patients with anti-MDA5 in a large Mediterranean cohort of DM patients from a single center, and analyze the feasibility of detecting this autoantibody in patient sera using new assays with commercially available recombinant MDA5. The study included 117 white adult patients with DM, 15 (13%) of them classified as clinically amyopathic dermatomyositis (CADM). Clinical manifestations were analyzed, with special focus on interstitial lung disease and its severity. Determination of anti-MDA5 antibodies was performed by a new ELISA and immunoblot technique. In sera, from 14 (12%) DM patients (8 CADM), MDA5 was recognized by ELISA, and confirmed by immunoblot. Eight of the 14 anti-MDA5-positive patients (57.14%) presented rapidly-progressive interstitial lung disease (RP-ILD) versus 3 of 103 anti-MDA5-negative patients (2.91%) (P<0.05; OR: 44.4, 95% CI 9.3–212). The cumulative survival rate was significantly lower in anti-MDA5-positive patients than in the remainder of the series (P<0.05). Patients with anti-MDA5-associated ILD presented significantly lower 70-month cumulative survival than antisynthetase-associated ILD patients. Among the cutaneous manifestations, only panniculitis was significantly associated with the presence of anti-MDA5 antibodies (P<0.05; OR: 3.85, 95% CI 1.11–13.27). These findings support the reliability of using commercially available recombinant MDA5 for detecting anti-MDA5 antibodies and confirm the association of these antibodies with RP-ILD in a large series of Mediterranean patients with DM. |
| format | Article |
| id | doaj-art-ef9dfac2b2bc45ceb320fe628735996d |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-ef9dfac2b2bc45ceb320fe628735996d2025-08-20T02:22:05ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/290797290797Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with DermatomyositisMoises Labrador-Horrillo0Maria Angeles Martinez1Albert Selva-O'Callaghan2Ernesto Trallero-Araguas3Eva Balada4Miquel Vilardell-Tarres5Cándido Juárez6Internal Medicine Department, Vall D’Hebron General Hospital, Universitat Autonoma de Barcelona, Passeig Vall D’Hebron 119-129, 08035 Barcelona, SpainImmunology Department, Hospital de La Santa Creu I Sant Pau, Universitat Autonoma de Barcelona, Barcelona, SpainInternal Medicine Department, Vall D’Hebron General Hospital, Universitat Autonoma de Barcelona, Passeig Vall D’Hebron 119-129, 08035 Barcelona, SpainInternal Medicine Department, Vall D’Hebron General Hospital, Universitat Autonoma de Barcelona, Passeig Vall D’Hebron 119-129, 08035 Barcelona, SpainInternal Medicine Department, Vall D’Hebron General Hospital, Universitat Autonoma de Barcelona, Passeig Vall D’Hebron 119-129, 08035 Barcelona, SpainInternal Medicine Department, Vall D’Hebron General Hospital, Universitat Autonoma de Barcelona, Passeig Vall D’Hebron 119-129, 08035 Barcelona, SpainImmunology Department, Hospital de La Santa Creu I Sant Pau, Universitat Autonoma de Barcelona, Barcelona, SpainA new myositis-specific autoantibody directed against melanoma differentiation-associated gene 5 (anti-MDA5) has been described in patients with dermatomyositis (DM). We report the clinical characteristics of patients with anti-MDA5 in a large Mediterranean cohort of DM patients from a single center, and analyze the feasibility of detecting this autoantibody in patient sera using new assays with commercially available recombinant MDA5. The study included 117 white adult patients with DM, 15 (13%) of them classified as clinically amyopathic dermatomyositis (CADM). Clinical manifestations were analyzed, with special focus on interstitial lung disease and its severity. Determination of anti-MDA5 antibodies was performed by a new ELISA and immunoblot technique. In sera, from 14 (12%) DM patients (8 CADM), MDA5 was recognized by ELISA, and confirmed by immunoblot. Eight of the 14 anti-MDA5-positive patients (57.14%) presented rapidly-progressive interstitial lung disease (RP-ILD) versus 3 of 103 anti-MDA5-negative patients (2.91%) (P<0.05; OR: 44.4, 95% CI 9.3–212). The cumulative survival rate was significantly lower in anti-MDA5-positive patients than in the remainder of the series (P<0.05). Patients with anti-MDA5-associated ILD presented significantly lower 70-month cumulative survival than antisynthetase-associated ILD patients. Among the cutaneous manifestations, only panniculitis was significantly associated with the presence of anti-MDA5 antibodies (P<0.05; OR: 3.85, 95% CI 1.11–13.27). These findings support the reliability of using commercially available recombinant MDA5 for detecting anti-MDA5 antibodies and confirm the association of these antibodies with RP-ILD in a large series of Mediterranean patients with DM.http://dx.doi.org/10.1155/2014/290797 |
| spellingShingle | Moises Labrador-Horrillo Maria Angeles Martinez Albert Selva-O'Callaghan Ernesto Trallero-Araguas Eva Balada Miquel Vilardell-Tarres Cándido Juárez Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis Journal of Immunology Research |
| title | Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis |
| title_full | Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis |
| title_fullStr | Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis |
| title_full_unstemmed | Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis |
| title_short | Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis |
| title_sort | anti mda5 antibodies in a large mediterranean population of adults with dermatomyositis |
| url | http://dx.doi.org/10.1155/2014/290797 |
| work_keys_str_mv | AT moiseslabradorhorrillo antimda5antibodiesinalargemediterraneanpopulationofadultswithdermatomyositis AT mariaangelesmartinez antimda5antibodiesinalargemediterraneanpopulationofadultswithdermatomyositis AT albertselvaocallaghan antimda5antibodiesinalargemediterraneanpopulationofadultswithdermatomyositis AT ernestotralleroaraguas antimda5antibodiesinalargemediterraneanpopulationofadultswithdermatomyositis AT evabalada antimda5antibodiesinalargemediterraneanpopulationofadultswithdermatomyositis AT miquelvilardelltarres antimda5antibodiesinalargemediterraneanpopulationofadultswithdermatomyositis AT candidojuarez antimda5antibodiesinalargemediterraneanpopulationofadultswithdermatomyositis |